Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | IL1RN | P18510 | 1/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL28258745 | 0.97 | KEAP1 (0.95) | KEAP1PGRNR3C2CA1CA2 | |
| Hydrogen Sulfide SCHEMBL27698561 | 0.97 | KEAP1 (0.95) | KEAP1PGRNR3C2CA1CA2 | |
| SCHEMBL11512295 | 0.97 | KEAP1 (0.95) | KEAP1PGRNR3C2CA1CA2 | |
| Hydrochloric Acid SCHEMBL27365433 | 0.97 | KEAP1 (0.95) | KEAP1PGRNR3C2CA1CA2 | |
| SCHEMBL1358244 | 0.91 | KEAP1 (0.83) | KEAP1PGRNR3C2CA1CA2 | |
| SCHEMBL9479898 | 0.91 | KEAP1 (0.83) | KEAP1PGRNR3C2CA1CA2 | |
| Boric Acid SCHEMBL6312485 | 0.91 | KEAP1 (0.83) | KEAP1PGRNR3C2CA1CA2 | |
| SCHEMBL27715693 | 0.87 | KEAP1 (0.76) | KEAP1PGRNR3C2CA1CA2 | |
| Ethyl Chloride SCHEMBL27421992 | 0.87 | KEAP1 (0.76) | KEAP1PGRNR3C2CA1CA2 | |
| SCHEMBL9387480 | 0.87 | KEAP1 (0.76) | KEAP1PGRNR3C2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12004868-B2 | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel | SIGNPATH PHARMA INC. (US) | 2024-06-11 | — | — | US | claimed |
| US-20230084927-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | METABOMED LTD. (IL) | 2023-03-16 | — | — | US | claimed |
| CN-113200891-B | Preparation method of cis-N-styryl amide derivative | 华侨大学 | 2022-09-30 | — | — | CN | claimed |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | claimed |
| CN-113200891-A | Preparation method of cis-N-styryl amide derivative | 华侨大学 | 2021-08-03 | — | — | CN | claimed |
| EP-3326616-B1 | LIPOSOMAL MITIGATION OF DRUG-INDUCED LONG QT SYNDROME AND POTASSIUM DELAYED-RECTIFIER CURRENT | SIGNPATH PHARMA INC (US) | 2021-07-28 | — | — | EP | claimed |
| US-10617639-B2 | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current | SIGNPATH PHARMA, INC. (US) | 2020-04-14 | — | — | US | claimed |
| US-20200108056-A1 | Liposomal Mitigation of Drug-Induced Inhibition of the Cardiac IKR Channel | SIGNPATH PHARMA INC. | 2020-04-09 | — | — | US | claimed |
| US-20190320975-A1 | LIPOSOMAL MITIGATION OF DRUG-INDUCED INHIBITION OF THE CARDIAC IKR CHANNEL | SIGNPATH PHARMA INC. | 2019-10-24 | — | — | US | claimed |
| US-20190321293-A1 | Liposomal Mitigation of Drug-Induced Long QT Syndrome and Potassium Delayed-Rectifier Current | SIGNPATH PHARMA INC. | 2019-10-24 | — | — | US | claimed |
| JP-2597176-B2 | — | — | 1997-04-02 | — | — | JP | claimed |
| EP-0441282-B1 | Bichromophore methine and azamethine dyestuffs and a process for their transfer | BASF AG (DE) | 1993-12-15 | — | — | EP | claimed |
| EP-0441282-A1 | Bichromophore methine and azamethine dyestuffs and a process for their transfer | BASF Aktiengesellschaft (DE) | 1991-08-14 | — | — | EP | claimed |
| US-4996284-A | Heating a sulfonamide and epoxy resin in the presence of a Lewis Acid | EMPAK, INC. | 1991-02-26 | — | — | US | claimed |
| WO-1990013609-A1 | NOVEL FLUORESCENT PIGMENT COMPOSITIONS AND A PROCESS FOR THEIR PREPARATION AND USE OF SAME | MALLAVARAPU LEO X (US) | 1990-11-15 | — | — | WO | claimed |
| WO-1990012829-A1 | NOVEL EPOXY SULFONAMIDE-BASED RESINS, A PROCESS FOR THEIR PREPARATION AND USE OF SAME | MALLAVARAPU LEO X (US) | 1990-11-01 | — | — | WO | claimed |
| US-4929530-A | OXIDATIVE LEUCO DYES, PHOTO-OXIDIZERS, REDUCING AGENTS, ORGANIC SULFONAMIDES AND PHENOLIC COMPONENTS; EXPOSING TO LIGHT | FUJI PHOTO FILM CO., LTD. (JP) | 1990-05-29 | — | — | US | claimed |
| CN-1038451-A | Antiarrhythmics | PFIZER LTD (GB) | 1990-01-03 | — | — | CN | claimed |
| WO-1988005630-A1 | FUNGICIDAL COMPOSITIONS | SHELL AGRAR GMBH & CO. KG (DE) | 1988-08-11 | — | — | WO | claimed |
| CN-87108295-A | New alkane sulfonyl aniline derivative and its medicinal compositions and preparation method | — | 1988-07-13 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | KEAP1 576/4885PGR 1495/4885NR3C2 1764/4885 |
| US-20230084927-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | SLC2A4, SLC2A1, SLC2A2 | KEAP1 199/4885PGR 2664/4885NR3C2 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.